SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is currently trending as community discourse intensifies over reports regarding Donald Trump's significant financial gains from crypto and stock trading during his presidency. Supporters and critics remain deeply divided, with discussions centering on political loyalty, accusations of market manipulation, and the broader implications of his administration's policies on national and economic affairs.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is facing significant selling pressure as investors await the upcoming AGM for concrete execution updates and clarity on production scaling. While the community remains polarized by the stock's recent volatility, many continue to debate the company's long-term potential as a key player in photonics and AI infrastructure despite the current lack of widespread institutional revenue confirmation.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is experiencing heightened investor activity driven by a strategic partnership with Honda and growing anticipation surrounding the upcoming World Ducati Week, where the community expects potential updates on solid-state battery testing. While some investors remain skeptical about the timeline for commercial scale and the impact of insider stock sales, bullish sentiment is fueled by the company's progress in anode-free technology and its expansion into high-growth sectors like AI data center power.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

TQQQ is experiencing intense volatility and downward pressure as investors rotate out of semiconductor and tech holdings due to escalating geopolitical tensions in the Middle East and concerns over stretched AI valuations. The community is actively debating whether current price levels represent a high-conviction discount buying opportunity or a deeper correction for this leveraged ETF.

Bank of Montreal engages in the provision of banking and financial services to individuals and institutions. It operates through the following segments: Canadian Personal and Commercial Banking (Canadian P&C), United States Personal and Commercial Banking (U.S. P&C), BMO Wealth Management, BMO Capital Markets, and Corporate Services. The company was founded by Robert Armour, John C. Bush, Austin Cuvillier, George Garden, Horatio Gates, James Leslie, George Moffatt, John Richardson and Thomas A. Turner on June 23, 1817 and is headquartered in Montreal, Canada.

Bank of Montreal - MicroSectors Gold Miners 3X Leveraged ETN

The GDXU is currently experiencing extreme volatility as traders debate whether this sharp correction is a healthy shakeout for long-term gold bulls or the start of a deeper cyclical breakdown. The community is actively tracking technical support levels while highlighting the impact of interest rate expectations and the influence of institutional liquidity flows on leveraged mining assets.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is seeing significant upward momentum as investors react to a positive delivery beat and raised annual production guidance, fueling active community debate regarding the company's ability to successfully scale its R2 platform. Market participants are closely watching the stock's ability to maintain technical support levels amidst heavy institutional volume and ongoing discussions about Rivian's long-term competitive positioning against other major EV players.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is experiencing a significant surge, fueled by momentum from successful clinical data for its subcutaneous Briumvi treatment and growing speculation regarding a potential buyout as institutional interest climbs. The community is actively discussing the stock's transition toward record levels, often highlighting the significant short position and the potential for a squeeze as investor confidence in the company's long-term revenue growth intensifies.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

VanEck Gold Miners ETF (GDX) remains a focal point for investors navigating inflationary pressures and geopolitical uncertainty, with the community actively debating whether current price levels offer a robust entry point for long-term accumulation. Discussions center on the ETF's correlation with broader macroeconomic indicators, specifically the ongoing volatility in the gold spot price and the persistent influence of energy costs on mining margins.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix is currently trending as shareholders debate the company's long-term commercialization strategy, with community sentiment divided between those anticipating a major breakout driven by upcoming battery product adoption in the drone and smart eyewear sectors and those frustrated by persistent production delays and technical hurdles. Despite recent volatility, investors remain focused on potential institutional accumulation and strategic partnerships as the primary catalysts that could eventually shift the stock's performance.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is trending as investors weigh strong pivotal trial results for its Duchenne muscular dystrophy gene therapy against regulatory uncertainty and recent financial challenges. The community is actively discussing the company's long-term potential, the impact of recent clinical holds, and the market implications of its current cash runway.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Multi-Billion-Dollar Race to Defeat Glioblastoma: Why Investors Are Watching One of Oncology's Most Challenging Frontiers

Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types. $NTHI, $KZIA, $BNTX, $IBRX

Kazia Therapeutics Appoints James Levine as Chief Financial Officer

Kazia Therapeutics Appoints James Levine as Chief Financial Officer Kazia Therapeutics Appoints James Levine as Chief Financial Officer PR Newswire SYDNEY, June 2, 2026 SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a...

Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer

Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer PR Newswire SYDNEY, May 26, 2026 Planned Enrollment to Increase from 12 to 36 Patients Following Continued Encouraging...

Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform

Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform Kazia Therapeutics Strengthens Scientific...

Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform

Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug...

KZIA Stock Is Rising Today — What Does Its Data For Nuclear PD-L1 Degrader Show?

Equity

Kazia stated that across multiple preclinical models and patient-derived samples, NDL2 demonstrated reversal of immune exhaustion, suppression of metastatic biology, and enhanced anti-tumor activity.

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2) Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear...

Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer Kazia Therapeutics Reports...

Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End

Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End Kazia Therapeutics to Participate in J.P. Morgan Healthcare...

Is the Market Bullish or Bearish on Kazia Therapeutics Ltd?

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. It focuses on its Paxalisib program, which is designed to treat brain cancer. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Kazia Therapeutics Limited - ADR

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

KZIAKazia Therapeutics

Fundamentals

Latest KZIA News